An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib

Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%–75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the managemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ying, Tang, Huaping, Li, Jun, Li, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467641/
https://www.ncbi.nlm.nih.gov/pubmed/26089684
http://dx.doi.org/10.2147/OTT.S78925
_version_ 1782376392984363008
author Zhang, Ying
Tang, Huaping
Li, Jun
Li, Meng
author_facet Zhang, Ying
Tang, Huaping
Li, Jun
Li, Meng
author_sort Zhang, Ying
collection PubMed
description Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%–75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year.
format Online
Article
Text
id pubmed-4467641
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-44676412015-06-18 An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib Zhang, Ying Tang, Huaping Li, Jun Li, Meng Onco Targets Ther Original Research Lung cancer has the highest mortality rate of all cancers worldwide. A total of 70%–75% of all lung cancers are non-small cell lung cancer (NSCLC) with two-thirds presenting with locally advanced or metastatic disease at diagnosis. Brain metastasis is one of the most common problems in the management of NSCLC, worsening the prognosis and quality of life of NSCLC patients. The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib have been tested in patients with NSCLC and brain metastasis. Icotinib is a new type of oral EGFR-TKI. In this report, we describe a patient with lung adenocarcinoma cancer with brain metastases who received icotinib treatment and kept satisfactory health-related quality of life for 1 year. Dove Medical Press 2015-06-08 /pmc/articles/PMC4467641/ /pubmed/26089684 http://dx.doi.org/10.2147/OTT.S78925 Text en © 2015 Zhang et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Zhang, Ying
Tang, Huaping
Li, Jun
Li, Meng
An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title_full An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title_fullStr An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title_full_unstemmed An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title_short An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
title_sort active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467641/
https://www.ncbi.nlm.nih.gov/pubmed/26089684
http://dx.doi.org/10.2147/OTT.S78925
work_keys_str_mv AT zhangying anactivetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT tanghuaping anactivetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT lijun anactivetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT limeng anactivetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT zhangying activetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT tanghuaping activetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT lijun activetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib
AT limeng activetreatmentoflungadenocarcinomacancerwithbrainmetastasesicotinib

Ejemplares similares